LONDON, Sept. 7, 2015 /PRNewswire/ --
Asthma and COPD continue to be a health segments that present significant challenges to patients and the caregiver community. Patient adherence with prescribing instructions and treatment protocols remains sub-optimal across all patient categories, but particularly for the young and the elderly. This has led to significant interest on the part of device and combination product providers directed toward the development easier-to-use inhalers. Because they relax smooth muscles in the airways, bronchodilators are an indispensable tool for the treatment of upper respiratory diseases. The market entry of combination drug inhalers that deliver a bronchodilator and a corticosteroid from the same inhaler are providing important options for both clinicians and patients.
Highlights
- Analyzes the market for bronchodilator drugs delivered via oral inhalers
- Assesses inhalation device technology for delivering bronchodilators orally, and evaluates product technology issues and evolving market factors
- Provides detailed assessments of orally inhaled bronchodilator product segments, growth prospects and market potential
- Provides market data and forecasts for orally inhaled bronchodilators to 2022
- Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
- Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners
Executive Summary
Orally Inhaled Corticosteroid Market Overview
The Upper Respiratory Therapeutics Marketspace
Therapeutic Targets for Orally Inhaled Bronchodilators
Competing Drug Treatments
Demand Drivers
Technology Factors
Competitive Landscape
Asthma Market Risks and Opportunities
Global Patient Demographics
Regional Market Drivers
Pediatric Asthma -the Growing Therapeutic Need
Inhaler Technologies for Delivering Bonchodilators
Dry Powder Inhalers
DPI Formulation Technology
Characteristics and Parameters
DPI Excipients and Packaging
Metered Dose Inhalers
MDI Device Selection Criteria
Ease-of-Use Factors
Nebulizers
Inhaled Bronchodilators - Product Analysis, Market Data & Forecasts
Albuterol, Proventil HFA (MDI)
Albuterol, Ventolin HFA (MDI)
Albuterol, ProAir HFA (MDI)
Albuterol, Accuneb (Nebulizer)
Generic Albuterol (Nebulizer)
Albuterol/Ipratropium (Combuvent) Combination Drug Inhaler (MDI)
Albuterol/Ipratropium (Duoneb) Combination Drug Solution (Nebulizer)
Generic Albuterol/Ipratropium Combination Drug Solution (Nebulizer)
Fluticasone/Vilanterol (Breo Ellipta) Combination Drug Inhaler (DPI) Fluticasone/Salmeterol (Advair HFA) Combination Drug Inhaler (MDI)
Fluticasone/Salmeterol (Advair Diskus) Combination Drug Inhaler (DPI)
Formoterol, Foradil (DPI)
Formoterol, Perforomist (Nebulizer)
Formoterol/Mometasone (Dulera) Combination Drug Inhaler (MDI)
Ipratropium, Atrovent HFA (MDI)
Generic Ipratropium (Nebulizer)
Levalbuterol, Xopenex (Nebulizer)
Generic Levalbuterol (Nebulizer)
Levalbuterol, Xopenex HFA( MDI)
Salmeterol, Serevent (DPI)
Tiotropium, Spiriva (DPI)
Tiotropium, Spiriva Respimat (MDI)
Umeclidinium, Incruse Ellipta (DPI)
Umeclidinium/Vilanterol (Anoro) Combination Drug Inhaler (DPI)
Market Factors
Regulatory Issues
Patient Compliance
Prescribing Trends
Healthcare Economics
Regional Market Factors
Connected Devices
Market Sector Company Profiles
Download the full report: https://www.reportbuyer.com/product/2841930/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article